NEW YORK – Uppsala, Sweden-based proteomics firm Olink on Thursday priced its initial public offering of 17,647,058 common shares at $20 per share, for anticipated gross proceeds of $264.7 million before underwriting discounts, commissions, and other expenses.
The IPO includes 4,411,764 shares offered by the selling shareholders. Shares will be offered in the form of American depositary shares and are expected to begin trading on the Nasdaq Global Market under the symbol OLK on March 25, 2021.
The underwriters have been granted a 30-day option to purchase up to 2,647,058 additional shares from Knilo InvestCo, a selling shareholder. Knilo InvestCo, which is owned by Olink's current owner, private equity firm Summa Equity, will continue to be Olink's controlling shareholder.
Goldman Sachs and Morgan Stanley are acting as lead bookrunning managers for the offering, SVB Leerink as joint bookrunning manager, and BTIG as co-manager.